Hosted on MSN16d
Gilead and LEO Pharma link on programmes for inflammatory conditions
Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...
Hosted on MSN10d
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant ...
PMLiVE10d
Gilead’s Livdelzi approved by MHRA to treat primary biliary cholangitis in adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to ...
The Pharma Letter11d
The week in pharma: action, reaction and insight – week to January 17
Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...
PMLiVE7d
LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab
LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...
BioWorld8d
BioWorld, Deals and M&A
Gilead Sciences Inc. is moving further into inflammatory diseases in a potential $1.7 billion deal with Leo Pharma A/S around a preclinical oral signal transduction and activator of transcription 6 ...